NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters NowZacks Investment Research • 07/22/26
Lilly confirms date and conference call for second-quarter 2026 financial results announcementPRNewsWire • 07/22/26
Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% laterReuters • 07/21/26
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly.The Motley Fool • 07/21/26
Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugsWSJ • 07/21/26
Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?The Motley Fool • 07/20/26
The market for psychedelic drugs to treat mental health conditions gets a big buy signalCNBC • 07/19/26
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1The Motley Fool • 07/18/26
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight LossThe Motley Fool • 07/18/26
Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still WinThe Motley Fool • 07/17/26
IPO Stock Of The Week: This Eli Lilly Partner Soars 118% In Three MonthsInvestors Business Daily • 07/17/26